The magic of numbers: Malignant melanoma between science and pseudoscience

American Journal of Dermatopathology

Volumn 33, Issue 4, 2011, Pages 371-378

  Weyers, Wolfgang ^a  

^a Center for Dermatopathology   (Germany)

Author keywords

classification; melanoma; prognosis; staging

Indexed keywords

CANCER STAGING; HUMAN; LYMPH NODE DISSECTION; MELANOMA; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE;

HUMANS; MELANOMA; MITOSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; SKIN ULCER; SOCIETIES, MEDICAL;

EID: 79958282594     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181faab45     Document Type: Review

References (39)

1. Quaranta A, Siniscalchi M, Vallotigara G. Asymmetric tail-wagging by dogs to different emotive stimuli. Curr Biol. 2009;17:R199-R201. (Pubitemid 46401382)
2. Day CL Jr, Mihm MC Jr, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg. 1982;195:30-34. (Pubitemid 12194940)
3. Weinstock MA, Morris BT, Lederman JS, et al. Effect of BANS location on the prognosis of clinical stage I melanoma: new data and meta-analysis. Br J Dermatol. 1988;119:559-565.
4. Wong JH, Wanek L, Chang LJ, et al. The importance of anatomic site in prognosis in patients with cutaneous melanoma. Arch Surg. 1991;126: 486-489.
5. Bernengo MG, Reali UM, Doveil GC, et al. BANS: a discussion of the problem. Melanoma Res. 1992;2:157-162.
6. Woods JE, Taylor WF, Pritchard DJ, et al. Is the BANS concept for malignant melanoma valid? Am J Surg. 1985;150:452-455.
7. Cascinelli N, Vaglini M, Bufalino R, et al. BANS. A cutaneous region with no prognostic significance in patients with melanoma. Cancer. 1986; 57:441-444. (Pubitemid 16164590)
8. Law MM, Wong JH. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma. Am Surg. 1994;60:362-366. (Pubitemid 24142657)
9. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res. 1969;29:705-726.
10. Weyers W, Euler M, Diaz-Cascajo C, et al. Classification of cutaneous malignant melanoma. A reassessment of histopathologic criteria for the distinction of different types. Cancer. 1999;86:288-299. (Pubitemid 29327586)
11. Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol. 1969;55:39-67.
12. Koh HK, Michalik E, Sober AJ, et al. Lentigo malignamelanoma has no better prognosis than other types of melanoma. J Clin Oncol. 1984;2:994-1001. (Pubitemid 14026255)
13. Smith KJ, Barrett TL, Skelton HG III, et al. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989;13:931-939. (Pubitemid 19258503)
14. Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential. Results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010;34:314-326.
15. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
16. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
17. Kerns MJJ, Darst MA, Olsen TG, et al. Shrinkage of cutaneous specimens: formalin or other factors involved? J Cutan Pathol. 2008;35: 1093-1096.
18. Hudson-Peacock MJ, Matthews JNS, Lawrence CM. Relation between size of skin excision, wound, and specimen. J Am Acad Dermatol. 1995; 32:1010-1015.
19. Day CL, Lew RA, Mihm MC Jr, et al. The natural break points for primary-tumor thickness in clinical stage 1 melanoma. N Engl J Med. 1981;305:1155.
20. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648. (Pubitemid 32786276)
21. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-1576. (Pubitemid 37486620)
22. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol. 1969;97:459-468.
23. Williams WJ, Davies K, Jones WM, et al. Malignant melanoma of the skin: prognostic value of histology in 89 cases. Br J Cancer. 1968;22: 452-460.
24. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978;114:871-873. (Pubitemid 9202393)
25. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-432. (Pubitemid 26250527)
26. Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85:2391-2399. (Pubitemid 29244848)
27. Massi D, Borgognoni L, Franchi A, et al. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res. 2000;10: 153-164. (Pubitemid 30256878)
28. Schmidt-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res. 2001;11:619-626. (Pubitemid 33152353)
29. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. An analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498. (Pubitemid 36297779)
30. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134. (Pubitemid 46596766)
31. Frishberg DP, Balch C, Balzer BL, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med. 2009;133:1560-1567.
32. Jensen SL, Radfar A, Bhawan J. Mitoses in conventional melanocytic nevi. J Cutan Pathol. 2007;34:713-715. (Pubitemid 47256252)
33. Ding S, Soong SJ, Lin HY, et al. Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat. 2009;19: 732-747.
34. Balch CM, Houghton AN, Milton GW, et al. Cutaneous Melanoma. 2nd ed. Philadelphia, PA: J.B. Lippincott; 1992.
35. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001; 137:1169-1173. (Pubitemid 32847838)
36. Petersson F, Diwan AH, Ivan D, et al. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis, and survival. J Cutan Pathol. 2009;36: 1157-1163.
37. Ackerman AB. Mythology and numerology in the sphere of melanoma. Cancer. 2000;88:491-496.
38. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2007;24:4340-4346. (Pubitemid 46630793)
39. Smalley KS, Sondak VK, Weber JS. C-Kit signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009; 24:643-650.